Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01665144 · ClinicalTrials.gov registry record · Phase 3
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,651
- Enrollment target
NCT01665144 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,651 participants.
The verdict
NCT01665144, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,651 participants
- Enrollment target
Study Summary
Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).
Interventions
- DRUG Placebo
- DRUG BAF312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,651 participants |
| Start Date | 2012-12-20 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01665144
The ClinicalTrials.gov registry entry for NCT01665144 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,651 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01665144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01665144 about?
NCT01665144 is a clinical study titled "Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)". Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension ...
What is the current status of trial NCT01665144?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,651 participants. The study started on 2012-12-20. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT01665144?
The interventions under investigation include: Placebo (DRUG), BAF312 (DRUG).
Who is sponsoring clinical trial NCT01665144?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.